Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey Chan

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Leukemia|December 18, 2018
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndromeJorge E Cortes, Florian H Heidel, Andrzej Hellmann, et al.
Blood|April 19, 2011
Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemiaWilliam G Wierda, Thomas J Kipps, Jan Dürig, et al.
Annals of Hematology|April 30, 2022
A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromesMikkael A Sekeres, Michael Schuster, Magalie Joris, et al.
Leukemia|August 21, 2023
Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trialMikkael A Sekeres, Pau Montesinos, Jan Novak, et al.
American Journal of Hematology|August 4, 2018
Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study resultsJorge E Cortes, B Douglas Smith, Eunice S Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2010
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemiaWilliam G Wierda, Thomas J Kipps, Jirí Mayer, et al.
The Lancet. Haematology|December 22, 2015
Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trialUwe Platzbecker, Raymond S M Wong, Amit Verma, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Leukemia|December 18, 2018
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndromeJorge E Cortes, Florian H Heidel, Andrzej Hellmann, et al.
Blood|April 19, 2011
Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemiaWilliam G Wierda, Thomas J Kipps, Jan Dürig, et al.
Annals of Hematology|April 30, 2022
A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromesMikkael A Sekeres, Michael Schuster, Magalie Joris, et al.
Leukemia|August 21, 2023
Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trialMikkael A Sekeres, Pau Montesinos, Jan Novak, et al.
American Journal of Hematology|August 4, 2018
Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study resultsJorge E Cortes, B Douglas Smith, Eunice S Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2010
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemiaWilliam G Wierda, Thomas J Kipps, Jirí Mayer, et al.
The Lancet. Haematology|December 22, 2015
Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trialUwe Platzbecker, Raymond S M Wong, Amit Verma, et al.
Pageof 5